Nucala

News

GSK closes on approval of asthma hope depemokimab

GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.

News

GSK claims first approval for Nucala in COPD

GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.

News

GSK sets up Nucala and Dupixent showdown in COPD

GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.

News

GSK says Nucala hits the target in new COPD trial

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<

News

GSK’s twice-yearly asthma drug clears two phase 3 trials

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six

News

Weak data for Fasenra undermine AZ's ambitions for the drug

AstraZeneca's IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker's efforts to expand its label keep running into difficulties.

GSK closes on approval of asthma hope depemokimab

GSK claims first approval for Nucala in COPD

GSK sets up Nucala and Dupixent showdown in COPD

GSK says Nucala hits the target in new COPD trial

GSK’s twice-yearly asthma drug clears two phase 3 trials

Weak data for Fasenra undermine AZ's ambitions for the drug

Ambros' $125m for pain disorder drug, and other financings

How to meet your physicians where they are online

Nucala

Editor's Picks